What is H.C. Wainwright's price target for CLVS?

H.C. Wainwright's latest stated price target for Clovis Oncology Inc. (CLVS) is $9, from its action on Sep 21, 2021.

What is H.C. Wainwright's rating on CLVS?

H.C. Wainwright rates CLVS Neutral, a neutral rating, as of May 6, 2022.

When did H.C. Wainwright last change its view on CLVS?

On May 6, 2022, H.C. Wainwright downgrades to Neutral from Buy.

H.C. Wainwright CLVS price target and rating history

Clovis Oncology Inc. (CLVS) · Health Care

H.C. Wainwright rates Clovis Oncology Inc. (CLVS) Neutral with a $9 price target, as of its latest action on May 6, 2022. It has published 3 rating actions on CLVS since August 2021, including 0 upgrades and 1 downgrade.

Current rating: Neutral
Price target: $9
Median target, all firms: Too few
Actions on CLVS: 3

H.C. Wainwright price target on CLVS

H.C. Wainwright price target on CLVS, each point a stated target, August 2021 to September 2021.

Every H.C. Wainwright rating on CLVS

May 6, 2022
DowngradeH.C. Wainwright downgrades to Neutral from Buy
Sep 21, 2021
ReiterateH.C. Wainwright cuts its price target to $9 from $10, keeps Buy
Aug 5, 2021
ReiterateH.C. Wainwright cuts its price target to $10 from $12, keeps Buy

Questions about H.C. Wainwright and CLVS

What is H.C. Wainwright's price target for CLVS?: H.C. Wainwright's latest stated price target for Clovis Oncology Inc. (CLVS) is $9, from its action on Sep 21, 2021.
What is H.C. Wainwright's rating on CLVS?: H.C. Wainwright rates CLVS Neutral, a neutral rating, as of May 6, 2022.
When did H.C. Wainwright last change its view on CLVS?: On May 6, 2022, H.C. Wainwright downgrades to Neutral from Buy.

All H.C. Wainwright ratings CLVS news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.